Cladribine
Treatment for Multiple Sclerosis
Typical Dosage: 10mg/kg total cumulative dose over 2 years
Effectiveness
87%
Safety Score
40%
Clinical Trials
42
Participants
1.9K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
40
DangerousModerateSafe
Treatment Details
Dosage Range
10mg/kg total cumulative dose over 2 years
Time to Effect
3-6 months
Treatment Duration
Two annual treatment courses (lifetime effect)
Evidence Quality
HIGHNumber Needed to Treat (NNT)
4(Treat 4 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
5(Treat 5 patients to see 1 additional serious adverse event)
Confidence Score
90%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$80,000
Monitoring:$4,000
Side Effect Mgmt:$1,000
Total Annual:$85,000
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
POORICER
$240,000/QALY
QALYs Gained
1
Outcome-Based Costs
Cost per Responder
$103,658.54
Cost per Remission
$188,888.89
Comparison vs Fingolimod
Cost Difference
$-2,000/year
Less expensive
QALY Difference
+0.35 QALYs
Better outcomes
Dominance
No dominance
Cladribine Outcomes
for Multiple Sclerosis
Efficacy Outcomes
Overall Effectiveness
+87%
Response Rate
+82%
Remission Rate
+45%
Common Side Effects
Lymphopenia (Grade 3/4)
+25%
Headache
+21%
Nasopharyngitis
+18%
Upper respiratory tract infection
+16%
Herpes zoster
+2.1%
Active Clinical Trials
6 active trials recruiting for Cladribine in Multiple Sclerosis
Cladribine Tablets After Treatment With Natalizumab (CLADRINA)
NCT04178005ACTIVE NOT RECRUITINGPHASE4
40 participants
INTERVENTIONAL
Overland Park, United States +1 more
Started: Feb 19, 2020
Cladribine Tablets as an Exit Therapy Strategy
NCT06887426NOT YET RECRUITING
450 participants
OBSERVATIONAL
Strasbourg, France
Started: Jun 1, 2025
Cladribine Tablets Level of Response Predictors in Clinical Practice (CLODINA)
NCT05797740ACTIVE NOT RECRUITING
367 participants
OBSERVATIONAL
Brussels, Belgium +29 more
Started: Aug 3, 2023
Cladribine vs Placebo for Non-active Progressive Multiple Sclerosis (CLASP-MS).
NCT05961644RECRUITINGPHASE2, PHASE3
188 participants
INTERVENTIONAL
Warsaw, Poland
Started: Oct 3, 2022
ChariotMS - Cladribine to Halt Deterioration in People With Advanced Multiple Sclerosis
NCT04695080ACTIVE NOT RECRUITINGPHASE2, PHASE3
204 participants
INTERVENTIONAL
Belfast, United Kingdom +21 more
Started: Jun 25, 2021
Randomized Autologous heMatopoietic Stem Cell Transplantation Versus Alemtuzumab, Cladribine or Ocrelizumab for RRMS (RAM-MS)
NCT03477500ACTIVE NOT RECRUITINGPHASE3
100 participants
INTERVENTIONAL
Copenhagen, Denmark +7 more
Started: Mar 21, 2018
Completed Clinical Trials
12 completed trials for Cladribine in Multiple Sclerosis
Prospective Effectiveness and Safety Study of Cladribine in Participants Who Change First-line DMD Treatments for Multiple Sclerosis (CLAD CROSS)
NCT04934800COMPLETED
256 participants
OBSERVATIONAL
Eisenstadt, Austria +60 more
Started: Dec 10, 2019
Norwegian Study of Oral Cladribine and Rituximab in Multiple Sclerosis (NOR-MS)
NCT04121403COMPLETEDPHASE3
267 participants
INTERVENTIONAL
Drammen, Norway +10 more
Started: Oct 16, 2019
A Study of Suboptimally Controlled Participants Previously Taking Injectable DMDs for RMS (CLICK-MS)
NCT03933215COMPLETED
100 participants
OBSERVATIONAL
Little Rock, United States +17 more
Started: May 21, 2019
Cladribine Tablets: Collaborative Study to Evaluate Impact On Central Nervous System Biomarkers in Multiple Sclerosis
NCT03963375COMPLETEDPHASE4
47 participants
INTERVENTIONAL
St Louis, United States +4 more
Started: Oct 28, 2019
A Study of Suboptimally Controlled Participants Previously Taking Oral or Infusion DMDs for RMS (MASTER-2)
NCT03933202COMPLETED
291 participants
OBSERVATIONAL
Cullman, United States +65 more
Started: Jul 22, 2019
Drug-Drug Interaction of Cladribine and Pantoprazole in Multiple Sclerosis Subjects
NCT00938366COMPLETEDPHASE1
18 participants
INTERVENTIONAL
Started: Jan 1, 2008
CLARITY Extension Study
NCT00641537COMPLETEDPHASE3
867 participants
INTERVENTIONAL
Boulder, United States +115 more
Started: Feb 29, 2008
Evaluation of Quality of Life (QoL) in Subjects With Highly Active Relapsing Multiple Sclerosis (MS) (CLARIFY MS)
NCT03369665COMPLETEDPHASE4
485 participants
INTERVENTIONAL
Linz, Austria +91 more
Started: Jun 20, 2018
Evaluation of the Onset of Action in Highly Active MS (MAGNIFY)
NCT03364036COMPLETEDPHASE4
270 participants
INTERVENTIONAL
Sydney, Australia +53 more
Started: May 28, 2018
Extension to the MAGNIFY MS Trial on Mavenclad® (Magnify MS Extension)
NCT04783935COMPLETEDPHASE4
219 participants
INTERVENTIONAL
Liverpool, Australia +45 more
Started: Mar 10, 2021
Oral Cladribine in Early Multiple Sclerosis (MS)
NCT00725985COMPLETEDPHASE3
617 participants
INTERVENTIONAL
Phoenix, United States +157 more
Started: Dec 31, 2008
A Phase 2 Study of Cladribine Add-on to Interferon-beta (IFN-beta) Therapy in Multiple Sclerosis (MS) Subjects With Active Disease (ONWARD)
NCT00436826COMPLETEDPHASE2
172 participants
INTERVENTIONAL
Cullman, United States +38 more
Started: Nov 30, 2006
Showing 20 of 42 total trials